The first experience with dabigatran antidote in the University Hospital Pilsen
Authors:
MUDr. Jitka Šlechtová; MUDr. Zdeňka Hajšmanová; MUDr. Alena Lavičková; MUDr. Pavla Šigutová
Authors place of work:
Ústav klinické biochemie a hematologie LF UK a FN Plzeň
Published in the journal:
Čas. Lék. čes. 2016; 155: 442-444
Category:
Case report
Summary
Dabigatran (Pradaxa, Boehringer Ingelheim) is the first direct oral thrombin (FIIa) inhibitor. It is indicated for thromboprophylaxis in patients undergoing elective total replacement hip or knee joint surgery or for the primary or secondary prophylaxis of elderly patients with non-valvular atrial fibrillation or for deep vein thrombosis and pulmonary embolism treatment and prophylaxis. Idarucizumab (Praxbind, Boehringer Ingelheim) is a specific monoclonal antibody fragment indicated in patients treated with dabigatran. It is recommended when reversal of anticoagulant effect of dabigatran is needed especially in cases of life-threatening bleeding, for emergency surgery or urgent procedures purposes. In this article, there is a summary of our clinical and laboratory experience with reversal effect of idarucizumab in our five patients.
Keywords:
dabigatran, idarucizumab, thrombin, diluted thrombin test
Zdroje
1. Van Ryn J et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant aktivity. J Thromb Haemost 2010; 103: 1116–1127.
2. Stangier J et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47–59.
3. Penka M, Michalcová J et al. Idarucizumab (Praxbind) – studie RE-VERSE AD. Hypertenze & kardiovaskulární prevence 2016; 5: 48–54.
4. Douxfils J, Mullier F, Robert S et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. J Thromb Haemost 2012; 107: 985–997.
5. Syed YY. Idarucizumab: a review as a reversal agent for dabigatran. Am J Cardiovasc Drugs 2016; 16: 297–304.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- Avascular necrosis of the femoral head
- Femoroacetabular impingement − treatment options
- Rehabilitation after total knee and hip arthroplasty
- Limb shortening in the management of leg length discrepancy